<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184960</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2019.341</org_study_id>
    <nct_id>NCT04184960</nct_id>
  </id_info>
  <brief_title>AG &amp; IM in CA Stomach Protocol</brief_title>
  <official_title>Performance of Endoscopic and Histological Criteria of Atrophic Gastritis and Intestinal Metaplasia in Predicting Risk of Gastric Cancer - a Multicenter Case Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center prospective case control study aiming to compare different methods of
      risk stratification models in predicting the risk of gastric cancer development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The case control study would compare which type of assessment (Endoscopic / histological) is
      more accurate in predicting the risk of gastric cancer development.

      The risk factor assessment would be based on the following criteria.

      Endoscopic assessment:

        1. Atrophic gastritis, based on Kimura Takemoto Classification

        2. Kyoto classification of gastritis

        3. Intestinal metaplasia, based on Endoscopic Mapping and Grading of Intestinal Metaplasia
           (EGGIM) Histological assessment (Based on random biopsies)

      1. Operative Links on Gastritis Assessment 2. Operative Links on Gastric Intestinal
      Metaplasia
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic grading of atrophic gastritis (Kimura Takemoto Classification)</measure>
    <time_frame>Cross sectional study, day 0</time_frame>
    <description>Endoscopic description of severity of gastric atrophy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endoscopic grading of intestinal metaplasia (EGGIM)</measure>
    <time_frame>Cross sectional study, day 0</time_frame>
    <description>Endoscopic mapping of degree of intestinal metaplasia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kyoto classification of gastritis</measure>
    <time_frame>Cross sectional study, day 0</time_frame>
    <description>Descriptive findings of gastritis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Operative links on gastritis assessment (OLGA)</measure>
    <time_frame>Cross sectional study, day 0</time_frame>
    <description>Biopsy based risk stratification panel based on severity of atrophic gastritis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Operative links on gastric intestinal metaplasia (OLGIM)</measure>
    <time_frame>Cross sectional study, day 0</time_frame>
    <description>Biopsy based risk stratification panel based on severity of intestinal metaplasia</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Atrophic Gastritis</condition>
  <condition>Intestinal Metaplasia</condition>
  <arm_group>
    <arm_group_label>Gastric cancer cohort</arm_group_label>
    <description>Cohort of patients with gastric cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-gastric cancer cohort</arm_group_label>
    <description>Cohort of patients without gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gastroscopy and gastric biopsies</intervention_name>
    <description>Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM</description>
    <arm_group_label>Gastric cancer cohort</arm_group_label>
    <arm_group_label>Non-gastric cancer cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 random biopsies would be taken in specific location of the stomach during gastroscopy.
      (Lesser curvature mid antrum, greater curvature mid antrum, lesser curvature mid corpus,
      greater curvature mid corpus)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with or without gastric cancer undergoing elective endoscopy would be recruited if
        they fulfil inclusion and exclusion criteria. Subsequently they would be analysed based on
        &quot;Gastric cancer&quot; and &quot;Non-gastric cancer&quot; cohorts.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Two groups of patients would be recruited in this case control study.

          1. Gastric neoplasia group Patients with newly diagnosed or history of cancer of stomach
             or gastric high grade dysplasia.

          2. Control group Patients with no prior history of gastric dysplasia or cancer

        Inclusion criteria:

          1. Age 40 or above

          2. Undergo elective upper gastrointestinal endoscopy

        Exclusion criteria:

          1. Patients with history of gastrectomy

          2. Patients with severe thrombocytopenia (Platelet count &lt;50) or coagulopathy (INR &gt; 1.5
             or on anticoagulation)

          3. Contraindication to upper gastrointestinal endoscopy

          4. Allergy towards sedative agents (Midazolam / Diazepam) or local anaesthetic spray
             (Lignocaine)

          5. Patients who cannot give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hon Chi Yip</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hon Chi Yip, FRCSEd(Gen)</last_name>
    <phone>+852 35052627</phone>
    <email>hcyip@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hon Chi Yip, FRCSEd (Gen)</last_name>
      <phone>+852 35052627</phone>
      <email>hcyip@surgery.cuhk.edu.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noriya Uedo</last_name>
      <email>noriya.uedo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Weiquan Li</last_name>
      <email>james.li.w.q@singhealth.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital and Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rapat Pittayanon, MD, MSc</last_name>
      <email>rapat125@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Hon Chi Yip</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastroscopy</keyword>
  <keyword>Atrophic gastritis</keyword>
  <keyword>Intestinal metaplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

